July 18, 2024 10:32 AM EDTUpdated 04:32 PM

J&J ditches epilepsy development with Addex, blindsiding 20-year partner

Kyle LaHucik

Senior Reporter

Johnson & Johnson has discontinued investment in an epilepsy program out of 20-year partner Addex Therapeutics a few months after the Geneva-based biotech’s drug flunked …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J ditches epilepsy development with Addex, blindsiding 20-year partner

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Arrowhead spotlights key pancreatitis figures from Phase 3 lipid disease study to differentiate itself from Ionis

Updated: Alnylam’s new Phase 3 ATTR data bring uncertainty to standard of care ambitions

Sanofi’s BTK inhibitor goes 1-for-3 in key MS trials, slows disability progression

Ipsen sells priority review voucher for highest price since 2016

Novo offers detailed look at semaglutide’s cardiac outcomes in Phase 3 trial as it tees up resubmission

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

J&J ditch­es epilep­sy de­vel­op­ment with Ad­dex, blind­sid­ing 20-year part­ner

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Ar­row­head spot­lights key pan­cre­ati­tis fig­ures from Phase 3 lipid dis­ease study to dif­fer­en­ti­ate it­self from Io­n­is

Up­dat­ed: Al­ny­lam’s new Phase 3 AT­TR da­ta bring un­cer­tain­ty to stan­dard of care am­bi­tions

Sanofi’s BTK in­hibitor goes 1-for-3 in key MS tri­als, slows dis­abil­i­ty pro­gres­sion

Ipsen sells pri­or­i­ty re­view vouch­er for high­est price since 2016

No­vo of­fers de­tailed look at semaglu­tide’s car­diac out­comes in Phase 3 tri­al as it tees up re­sub­mis­sion

How to se­cure full en­roll­ment and a 30x ROI: A con­ver­sa­tion with the CEO of the bou­tique en­roll­ment agency do­ing just ...

J&J ditches epilepsy development with Addex, blindsiding 20-year partner

Arrowhead spotlights key pancreatitis figures from Phase 3 lipid disease study to differentiate itself from Ionis

Updated: Alnylam’s new Phase 3 ATTR data bring uncertainty to standard of care ambitions

Sanofi’s BTK inhibitor goes 1-for-3 in key MS trials, slows disability progression

Ipsen sells priority review voucher for highest price since 2016

Novo offers detailed look at semaglutide’s cardiac outcomes in Phase 3 trial as it tees up resubmission

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...